Hims & Hers to offer compounded peptides
The Hill · August 11, 2026Original source ↗
What happened
Hims & Hers Health announced plans to sell compounded peptides during a recent earnings call. CEO Andrew Dudum stated that the company is developing a high-quality peptides experience, including U.S. manufactured products, clinical guidance, and blood testing.
Why it matters
This development could provide consumers with new options for peptide treatments.
How this story affects people
How does this story affect you if you are interested in peptide treatments?
This announcement may provide you with new options for accessing peptide therapies. The company's focus on U.S. manufacturing and clinical guidance could enhance the quality and safety of these treatments.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your RippleMore stories
- HealthCalifornia to monitor pesticides with per- and polyfluoroalkyl substances
- HealthOver 44,000 individuals file legal objections to Palantir's NHS data platform
- HealthHealthcare funding from Congress may expire due to unspent allocations
- HealthGirl Hospitalized After Consuming Raw Milk Sold by Unlicensed Farmer